Vaccine-Induced Immunity and Prevention of CIRDC

Introduction 

Vaccination plays a critical role in controlling canine infectious respiratory disease complex. While several vaccines are available against B. bronchiseptica, vaccines targeting CPI are less commonly included in traditional oral vaccine formulations^1,2. 

Recent research has focused on bivalent oral vaccines combining CPI and B. bronchiseptica antigens to provide broader respiratory protection. 

Immune Response Following Oral Vaccination 

Systemic Immune Response 

The bivalent oral vaccine induces strong humoral immunity¹: 

• CPI neutralizing antibody seroconversion occurred in 91% of vaccinated dogs 

• 100% seroconversion was observed for B. bronchiseptica antibodies 

Post-challenge antibody responses were approximately 10 times higher in vaccinated dogs compared to placebo animals, suggesting strong immunological memory formation¹. 

Mucosal Immune Response 

Oral vaccination stimulates mucosa-associated lymphoid tissue (MALT), especially the nasopharyngeal tonsils. 

Mucosal immunity prevents^1,2: 

• Pathogen adhesion 

• Viral replication 

• Mucosal tissue invasion 

The specialised vaccine delivery applicator produces a fine mist that improves antigen exposure to mucosal immune tissues. 

Clinical Protection Outcomes 

Protection Against CPI¹ 

Vaccinated dogs demonstrated: 

• 83% reduction in viral shedding duration 

Reduced viral shedding helps: 

• Decrease environmental contamination 

• Reduce outbreak spread 

Protection Against B. bronchiseptica¹ 

Vaccinated animals showed: 

• 65% reduction in coughing duration 

• Lower disease incidence compared to placebo controls 

Clinical disease occurred in 74% of placebo dogs, significantly higher than vaccinated animals. 

Duration of Immunity¹ 

Protection was demonstrated for at least 12 months after a single vaccine dose. 

Antibody titers against B. bronchiseptica peaked around 35 days post-vaccination and remained stable for one year. 

Epidemiological Impact 

Reduced coughing frequency is important because coughing increases airborne droplet dispersion. Vaccination therefore reduces both clinical disease severity and transmission potential within canine populations. 

Importance of Mucosal Vaccination 

Mucosal vaccines provide: 

• Local immune defense at infection entry sites 

• Rapid pathogen neutralization 

• Improved respiratory disease control 

Respiratory pathogens typically first interact with mucosal surfaces, making mucosal immunity highly relevant. 

Vet Pearls 

• Oral vaccines are particularly useful for improving compliance in multi-dog environments. 

• MALT stimulation is key for respiratory pathogen prevention. 

• Reducing coughing directly reduces environmental pathogen spread. 

Conclusion 

Bivalent oral vaccination provides effective long-term protection against CIRDC pathogens. A single vaccine dose can provide protection for at least 12 months while significantly reducing viral shedding and clinical disease severity. 

Vaccination programs remain essential tools for controlling respiratory outbreaks in high-density canine populations. 

References 

1. Wiechert-Brown SA, Classe HM, Dant JC, LaFleur RL, Xu Z, Tarpey I. One year duration of immunity of a combination Bordetella bronchiseptica-canine parainfluenza oral vaccine in dogs. Frontiers in Veterinary Science. 2025 Oct 14;12:1634190. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1634190/pdf  

2. Scott‐Garrard M, Wang X, Chiang YW, David F. Thirteen‐month duration of immunity of an oral canine vaccine against challenge with Bordetella bronchiseptica. Veterinary record open. 2020;7(1):e000423. https://bvajournals.onlinelibrary.wiley.com/doi/10.1136/vetreco-2020-000423